Charles Schwab’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-178,879
| Closed | -$313K | – | 3562 |
|
|
2025
Q1 | $313K | Hold |
178,879
| – | – | ﹤0.01% | 3196 |
|
|
2024
Q4 | $283K | Hold |
178,879
| – | – | ﹤0.01% | 3281 |
|
|
2024
Q3 | $281K | Hold |
178,879
| – | – | ﹤0.01% | 3297 |
|
|
2024
Q2 | $319K | Buy |
+178,879
| New | +$415K | ﹤0.01% | 3353 |
|
|
2021
Q2 | – | Sell |
-2,676
| Closed | -$42K | – | 3520 |
|
|
2021
Q1 | $42K | Buy |
+2,676
| New | +$39.6K | ﹤0.01% | 3456 |
|
|
2017
Q2 | – | Sell |
-515
| Closed | -$102K | – | 3128 |
|
|
2017
Q1 | $102K | Hold |
515
| – | – | ﹤0.01% | 3017 |
|
|
2016
Q4 | $140K | Hold |
515
| – | – | ﹤0.01% | 3017 |
|
|
2016
Q3 | $204K | Hold |
515
| – | – | ﹤0.01% | 2915 |
|
|
2016
Q2 | $179K | Buy |
515
+184
| +56% | +$132K | ﹤0.01% | 2976 |
|
|
2016
Q1 | $275K | Hold |
331
| – | – | ﹤0.01% | 2803 |
|
|
2015
Q4 | $347K | Hold |
331
| – | – | ﹤0.01% | 2805 |
|
|
2015
Q3 | $260K | Hold |
331
| – | – | ﹤0.01% | 2880 |
|
|
2015
Q2 | $435K | Buy |
331
+137
| +71% | +$221K | ﹤0.01% | 2723 |
|
|
2015
Q1 | $395K | Buy |
194
+43
| +28% | +$93.5K | ﹤0.01% | 2720 |
|
|
2014
Q4 | $291K | Hold |
151
| – | – | ﹤0.01% | 2852 |
|
|
2014
Q3 | $124K | Hold |
151
| – | – | ﹤0.01% | 3027 |
|
|
2014
Q2 | $146K | Hold |
151
| – | – | ﹤0.01% | 3046 |
|
|
2014
Q1 | $164K | Hold |
151
| – | – | ﹤0.01% | 2991 |
|
|
2013
Q4 | $134K | Hold |
151
| – | – | ﹤0.01% | 3031 |
|
|
2013
Q3 | $168K | Hold |
151
| – | – | ﹤0.01% | 2963 |
|
|
2013
Q2 | $181K | Buy |
+151
| New | +$144K | ﹤0.01% | 2938 |
|
Other funds holding RGLS
Charles Schwab's RGLS Position: Q2 2025 in Review
Charles Schwab sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 178,879 shares — an estimated $313K sold.
Charles Schwab first reported a position in RGLS in Q2 2013 and held it in 21 quarters. The position peaked at $435K in Q2 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- Charles Schwab reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- Charles Schwab sold 178,879 Regulus Therapeutics shares in Q2 2025, an estimated $313K.
- Charles Schwab first reported a position in Regulus Therapeutics in Q2 2013 and held it in 21 quarters.
- Charles Schwab's Regulus Therapeutics position peaked at $435K in Q2 2015.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.